AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02637583
Drug: PCV13
RxNorm normalized name: pneumococcal 13-valent conjugate vaccine (PCV13) 0.5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
Trial: NCT01209351
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03236792
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
Trial: NCT00506181
Drug: probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day.
Trial: NCT00506181
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00296335
Drug: Mitomycin, doxifluridine and cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
Trial: NCT00296335
Drug: Mitomycin and doxifluridine
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
Trial: NCT00613496
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
Trial: NCT04068246
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet plus plus Methotrexate 7.5 mg weekly
Trial: NCT03478696
Drug: Placebo to match FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to FF/UMEC/VI will be administered via ELLIPTA once daily in the morning.
Trial: NCT03094156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of placebo \[to be taken orally, with 240 mL of potable water\]
Trial: NCT03094156
Drug: BIA 6-512
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg \[to be taken orally, with 240 mL of potable water\]
Trial: NCT03094156
Drug: Madopar® 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa/benserazide immediate release tablets 200mg/50mg \[to be taken orally, with 240 mL of potable water\]
Trial: NCT03094156
Drug: Comtan®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone 200 mg tablets \[to be taken orally, with 240 mL of potable water\]
Trial: NCT00997893
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol pill (1 mg)
Trial: NCT00997893
Drug: Soy Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo pill (0mg Soy Phytoestrogen)
Trial: NCT00997893
Drug: MPA Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral placebo pill (0mg MPA)
Trial: NCT02372461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is an non inferiority trial, the intervention is a placebo
Trial: NCT00140972
Drug: MK0663; etoricoxib / Duration of Treatment:4 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00140972
Drug: Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02620592
Drug: ZYDPLA1 tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
Trial: NCT04452669
Drug: VentaProst (inhaled epoprostenol delivered via a dedicated delivery system)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VentaProst delivered for up to 10 days via mechanical ventilation at a dose range that may be up or down titrated to a patient's clinical condition.
Trial: NCT02620592
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
Trial: NCT00003425
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00765492
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04801836
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet once per day
Trial: NCT05641311
Drug: ALXN1840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet for oral use.
Trial: NCT01315886
Drug: SL fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
Trial: NCT02524288
Drug: ENG-E2 125 μg/300 μg vaginal ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
Trial: NCT01311180
Drug: Sensoril®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Trial: NCT01311180
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
Trial: NCT02558218
Drug: tobradex quid (Standard)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication (tobradex quid for 20 days)
Trial: NCT02107378
Drug: Standard of Care (Paclitaxel or topotecan or doxorubicin)
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
Trial: NCT01026064
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax (250 mg oral capsule).
Trial: NCT01026064
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01980095
Drug: RHB-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:~* Rifabutin 150 mg~* Amoxicillin 3000 mg~* Omeprazole 120 mg~Subjects will take study drug every 8 hours with food for 14 consecutive days.
Trial: NCT01980095
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
Trial: NCT00488540
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suppository
Trial: NCT02009488
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo capsule (inactive medication) once daily.
Trial: NCT01099891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, Spray type, Twice a day
Trial: NCT03671525
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two coconut oil capsules that mimic the size and color of the nimodipine capsules
Trial: NCT03868033
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Use Zoledronic acid as a sequential therapy after denosumab treatment for more than 2 years
Trial: NCT03744949
Drug: Remifentanil dose 0.5 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be given (dosage of 0.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Trial: NCT03744949
Drug: Remifentanil dose 1 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be given (dosage of 1 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Trial: NCT03744949
Drug: Remifentanil dose 1.5 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be given (dosage of 1.5 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Trial: NCT03744949
Drug: Remifentanil dose 2 ug/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil will be given (dosage of 2 µg/kg of adjusted body weight bolus) from an infusion pump over 30 seconds
Trial: NCT00873600
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02732314
Drug: Investigational OTC Cream
RxNorm normalized name: INVESTIGATIONAL AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00203229
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
Trial: NCT02279667
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral suspension 50 mg/mL
Trial: NCT02279667
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tablet
Trial: NCT02279667
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg tablet
Trial: NCT01311336
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
Trial: NCT04057807
Drug: LPS
RxNorm normalized name: ALPS LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS (0.4 ng/kg)
Trial: NCT00537563
Drug: Telithromycin
RxNorm normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01482013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once a day for 28 days.
Trial: NCT01382342
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg daily
Trial: NCT00889694
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 2 capsules per time, 3 times per day for 12 weeks.
Trial: NCT03477396
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor per treating investigator's discretion
Trial: NCT01120106
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline continuous infusion
Trial: NCT01193049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets as a single oral dose on Day 1 of each study period
Trial: NCT01951911
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01544062
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Trial: NCT01544062
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
Trial: NCT00092898
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01228513
Drug: ZK245186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical application
Trial: NCT01228513
Drug: Placebo (vehicle without active ingredient)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily topical application
Trial: NCT00300040
Drug: 6% Hydroxyethylstarch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250ml for intravenous infusion
Trial: NCT01830842
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nonsmokers will be measured following placebo administration
Trial: NCT00919763
Drug: CD2027 Ointment 3 mcg/g, twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Ointment
Trial: NCT00919763
Drug: Vehicle Ointment, twice daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Ointment
Trial: NCT02792036
Drug: Maxitrol®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
Trial: NCT00256243
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
Trial: NCT00256243
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV once every 14 days x 2-4 cycles
Trial: NCT03560310
Drug: ASA 75-160 mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assess whether ticagrelor 90 mg twice daily and ASA 75-100 mg daily versus ASA 75-160 mg daily improves outcome after isolated coronary artery bypass grafting in patients with acute coronary syndrome
Trial: NCT00413179
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01677104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00207532
Drug: folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04267250
Drug: Ethinyl estradiol (EE) and levonorgestrel (LN)
RxNorm normalized name: estradiol / ethinyl estradiol / levonorgestrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet containing 30 mcg EE and 150 mcg LN.
Trial: NCT00547118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo tablet given 1 time per day for 112 days.
Trial: NCT03103971
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02248480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00165178
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
Trial: NCT00165178
Drug: E. coli asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensification Phase: In the muscle weekly. Dose will vary
Trial: NCT00165178
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
Trial: NCT00165178
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
Trial: NCT00165178
Drug: Methotrexate/Hydrocortisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
Trial: NCT00005608
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02214290
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
Trial: NCT02214290
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 750 mg placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
Trial: NCT03726268
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Trial: NCT03726268
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given per clinical provider discretion intraoperatively and in the immediate post-operative period (while patient remains in the post anesthesia care unit (PACU)).
Trial: NCT00649610
Drug: valdecoxib
RxNorm normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
Trial: NCT00649610
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac 75 mg twice daily (BID) for 7 days
Trial: NCT05283499
Drug: OPIOID
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic assignment
Trial: NCT05283499
Drug: NON-OPIOID
RxNorm normalized name: Non-opioid analgesic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic assignment
Trial: NCT02711826
Drug: Mycophenolic acid
RxNorm normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
Trial: NCT02711826
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
Trial: NCT00241423
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
Trial: NCT02885350
Drug: Spinal analgesia for labour pain
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
Trial: NCT02885350
Drug: Epidural analgesia for labour pain
RxNorm normalized name: Arthricare for Women Pain Relieving Nighttime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
Trial: NCT00324038
Drug: Codeine paracetamol
RxNorm normalized name: codeine and paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
Trial: NCT01514903
Drug: HIP0908
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SINGLE DOSE , CROSS OVER
Trial: NCT00483405
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
Trial: NCT02770430
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.~2. If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR.
Trial: NCT00741741
Drug: TMC278
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00410163
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
Trial: NCT00382616
Drug: Phosphatidylserine-Omega3
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00392223
Drug: Azithromycin microspheres
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo